Google Translate Limitations Disclaimer

The electronic translation service on the brainXchange website is hosted by Google Translate, an external translation service. The brainXchange does not guarantee or warrant the reliability, accuracy or completeness of any translated information. The basic translation goal is to capture the general information of the original English website content. If any questions arise related to the accuracy of the information contained in the translated website, please refer to the English version of the website.

Home > Events > Archived Webinars & Events > 2021 > The Impact of Lewy Body Dementia on Patients, Caregivers, and Society

The Impact of Lewy Body Dementia on Patients, Caregivers, and Society

Event Date: Sep 08, 2021

Related Resources l Recording

Lewy body dementia (LBD) is the second most common neurodegenerative cause of dementia after Alzheimer's disease (AD) and has various clinical manifestations that can negatively impact the quality of life of patients.

At the end of this webinar, participants should be able to:

Describe the various clinical features of LBD
Understand the negative effects of LBD on patients and caregivers
Appreciate the socioeconomic consequences of LBD
Name resources available to mitigate the impact of LBD on patients and caregivers

This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA).

Related Documents:

Lewy Body dementia, Alzheimer Society of Canada

Presenter(s):

Philippe Desmarais, MD, FRCPC, MHSc, Adjunct Clinical Professor, Department of Medicine, University of Montreal

Dr. Philippe Desmarais completed his medical training at the University of Montreal in 2011 and obtained is board certification in Internal Medicine in 2014 and in Geriatric Medicine in 2016. He has completed a clinical research fellowship in Cognitive Neurology in 2018 and obtained his MHSc in Translational Research in 2019 at the University of Toronto. Dr. Desmarais is an Internist-geriatrican at the Centre Hospitalier de l'Université de Montréal and an Adjunct Clinical Professor of Medicine at the University of Montreal. His clinical expertise is the diagnosis and management of non-Alzheimer neurocognitive disorders, specifically of frontotemporal lobar degeneration and alpha-synucleinopathies. He is particularly interested in the neuropsychiatric and behavioural manifestations of neurodegenerative disorders as well as their pharmacological treatments. Dr. Desmarais' research endeavours explore the clinico-radiological and clinico-pathological neural correlates of neuropsychiatric manifestations in older adults with neurodegenerative disorders.